Zora and ceramides in Science Daily
New blood test developed by Zora Biosciences was featured in Science Daily News on March 10, 2017.
The test predicst cardiovascular events in patients with or without coronary artery disease and the test is in use in the USA at Mayo Clinic. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes. Based on the ceramide levels a risk score is calculated.
Mayo Clinic presented its research on plasma ceramides at the American College of Cardiology’s 66th Annual Scientific Session. The study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart’s arteries.
Below is a link to the article: